Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
Clin Colorectal Cancer. 2023 Sep;22(3):327-338. doi: 10.1016/j.clcc.2023.06.001. Epub 2023 Jun 7.
Clin Colorectal Cancer. 2023.
PMID: 37355363
Free article.
Clinical Trial.
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K.
Denda T, et al.
Eur J Cancer. 2021 Sep;154:296-306. doi: 10.1016/j.ejca.2021.06.013. Epub 2021 Jul 22.
Eur J Cancer. 2021.
PMID: 34304054
Free article.
Clinical Trial.
Item in Clipboard
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M.
Komatsu Y, et al.
BMC Cancer. 2015 Sep 9;15:626. doi: 10.1186/s12885-015-1630-1.
BMC Cancer. 2015.
PMID: 26353772
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite